# Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma

> **NCT03702725** · PHASE1 · COMPLETED · sponsor: **Alliance Foundation Trials, LLC.** · enrollment: 14 (actual)

## Conditions studied

- Refractory Multiple Myeloma
- Multiple Myeloma in Relapse
- Multiple Myeloma

## Interventions

- **DRUG:** Ibrutinib
- **DRUG:** Lenalidomide
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT03702725
- **Lead sponsor:** Alliance Foundation Trials, LLC.
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-08-29
- **Primary completion:** 2024-09-27
- **Final completion:** 2024-10-04
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2026-01-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03702725

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03702725, "Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03702725. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*